Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation

Cox, Stephanie; Margot, Nicolas; Ram, Renee; Johnson, Audun; Miller, Michael D.; Callebaut, Christian

doi:10.1016/j.antiviral.2017.03.021

Search citation statements

Order By: Relevance

Paper Sections

Select...

Nucleoside Reverse Transcriptase Inhibitors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2024

Publication Types

Select...

Article4

Preprint1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the TDF-selected mutations have been reported to reduce ZDV susceptibility, making ZDV an option for treating viruses with TDF resistance but without TAMs. The prodrug TAF selects for many of the same DRMs selected by TDF [14][15][16]. The phenotypic effects of these DRMs on TDF and TAF are similar [14,15].…”

Section: Nucleoside Reverse Transcriptase Inhibitorsmentioning

confidence: 99%

Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update

Shafer

2017

The Journal of Infectious Diseases

View full text Add to dashboard Cite

As treatment options coalesce around a smaller number of antiretroviral drugs (ARVs), data are emerging on the drug resistance mutations (DRMs) selected by the most widely used ARVs and on the impact of these DRMs on ARV susceptibility and virological response to first- and later-line treatment regimens. Recent studies have described the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitors raltegravir and elvitegravir. Several small studies have described DRMs that emerge in patients receiving dolutegravir.

show abstract